Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
149 studies found for:    KRAS OR EGFR OR ALK OR PIK3CA OR HER2 OR BRAF OR ROS OR RET OR NRAS OR MET | lung cancer | Studies received from 01/01/2013 to 01/01/2014
Show Display Options
Rank Status Study
1 Active, not recruiting Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Ipilimumab;   Drug: Erlotinib;   Drug: Crizotinib;   Drug: Nivolumab
2 Recruiting A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Condition: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions: Drug: PF-06463922;   Drug: Crizotinib
3 Unknown  Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention:
4 Active, not recruiting Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Condition: HER2-mutant Non-Small Cell Lung Cancer
Interventions: Drug: neratinib;   Drug: temsirolimus
5 Active, not recruiting LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: Pemetrexed + cisplatin or pemetrexed + carboplatin
6 Active, not recruiting Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Condition: EGFR-Mutant Lung Cancer
Intervention: Drug: erlotinib
7 Completed A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib;   Drug: onartuzumab;   Drug: placebo
8 Completed Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
Conditions: Anaplastic Lymphoma Kinase (ALK);   Non-small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: AUY922
9 Active, not recruiting Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer
Intervention: Drug: defactinib (VS-6063)
10 Active, not recruiting
Has Results
A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: RO5452802
11 Recruiting A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Conditions: Lung Cancer;   Non-Small Cell Lung Cancer
Interventions: Drug: MEK162;   Drug: Erlotinib
12 Recruiting Analysis of Plasma Tumor DNA in Lung Cancer Patients
Condition: Non Small Cell Lung Cancer Patients
Intervention:
13 Recruiting MSC2156119J With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MSC2156119J;   Drug: Gefitinib;   Drug: Pemetrexed;   Drug: Cisplatin
14 Enrolling by invitation Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients
Condition: Nonsmall Cell Lung Cancer
Intervention: Device: ALK qPCR assay
15 Unknown  A Prospective Epidemiologic Study of ALK-Positive NSCLC in China
Condition: Non-small-cell Lung Cancer
Intervention:
16 Active, not recruiting Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Bortezomib;   Drug: Acyclovir
17 Recruiting Vandetanib in Advanced NSCLC With RET Rearrangement
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Vandetanib
18 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
19 Active, not recruiting Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Drug: Selumetinib;   Drug: Docetaxel;   Drug: Placebo;   Drug: Pegylated G-CSF
20 Unknown  Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Condition: EGFR Mutation Positive Non-small Cell Lung Cancer
Intervention: Drug: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.